Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection.
We present a case of serious treatment-refractory acyclovir- and foscarnet-resistant herpes simplex virus (HSV) type-1 orolingual infection that responded to oral cidofovir rinses after failure of acyclovir and foscarnet therapy. The use of 3% cidofovir in a saline rinse for refractory mucosal HSV infection appears promising but needs prospective evaluation.
Sims
C R
CR
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Thompson
K
K
Chemaly
R F
RF
Shpall
E J
EJ
Champlin
R E
RE
Safdar
A
A
D000287:Administration, Topical; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D024921:Drug Resistance, Multiple, Viral; D005260:Female; D018259:Herpesvirus 1, Human / Q000302:isolation & purification*; D006801:Humans; D016867:Immunocompromised Host; D008875:Middle Aged; D009067:Mouthwashes; D063065:Organophosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D033581:Stem Cell Transplantation; D013283:Stomatitis, Herpetic / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology
D000998:Antiviral Agents; D009067:Mouthwashes; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir